Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of AK112 plus pemetrexed and carboplatin versus placebo plus pemetrexed and carboplatin in EGFR-mutant non-squamous NSCLC after EGFR-TKI failure
CTR20213079Phase 3Active
- Sponsor
- Akeso, Inc.
- Start
- Jan 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc.. Started Jan 2022; status: active.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20213079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213079.